Contact and support
Need help, have a question, or want to contact the ResearchHub team?
© 2026 ResearchHub. Built for responsible scholarly connection.
Privacy-aware community infrastructureResearch graph
References from Regulatory patterns analysis of transcription factor binding site clustered regions and identification of key genes in endometrial cancer. Local targets link to admitted publications; unresolved targets remain external evidence.
10.3322/caac.21660
10.3322/caac.21660 · External reference
10.3322/caac.21654
10.3322/caac.21654 · External reference
10.1038/s41568-019-0177-x
10.1038/s41568-019-0177-x · External reference
Hysterectomy-Corrected Uterine Corpus Cancer Incidence Trends and Differences in Relative Survival Reveal Racial Disparities and Rising Rates of Nonendometrioid Cancers
10.1200/jco.19.00151 · 2019 · External reference
Phase III trial of doxorubicin plus cisplatin with or without paclitaxel plus filgrastim in advanced endometrial carcinoma: a Gynecologic Oncology Group Study
10.1200/jco.2004.07.184 · 2004 · External reference
Current recommendations and recent progress in endometrial cancer
2019 · External reference
A phase II study of frontline paclitaxel/carboplatin/bevacizumab, paclitaxel/carboplatin/temsirolimus, or ixabepilone/carboplatin/bevacizumab in advanced/recurrent endometrial cancer
10.1016/j.ygyno.2018.05.018 · 2018 · External reference
Randomized Phase II Trial of Carboplatin-Paclitaxel Compared with Carboplatin-Paclitaxel-Trastuzumab in Advanced (Stage III-IV) or Recurrent Uterine Serous Carcinomas that Overexpress Her2/Neu (NCT01367002): Updated Overall Survival Analysis
10.1158/1078-0432.ccr-20-0953 · 2020 · External reference
Effect of hysteroscopy on the peritoneal dissemination of endometrial cancer cells: a meta-analysis
10.1016/j.fertnstert.2011.07.1146 · 2011 · External reference
Accuracy of hysteroscopy in the diagnosis of endometrial cancer and hyperplasia - A systematic quantitative review
10.1001/jama.288.13.1610 · 2002 · External reference
10.1016/s0140-6736(15)00130-0
10.1016/s0140-6736(15)00130-0 · External reference
BGCS uterine cancer guidelines: Recommendations for practice
10.1016/j.ejogrb.2017.04.015 · 2017 · External reference
10.1038/ng.3562
10.1038/ng.3562 · External reference
Identification of nine new susceptibility loci for endometrial cancer
10.1038/s41467-018-05427-7 · 2018 · External reference
Genome-Wide Association Studies of Endometrial Cancer: Latest Developments and Future Directions
10.1158/1055-9965.epi-18-1031 · 2019 · External reference
10.1002/1878-0261.12727
10.1002/1878-0261.12727 · External reference
10.1371/journal.pmed.1002206
10.1371/journal.pmed.1002206 · External reference
10.1126/science.aal2380
10.1126/science.aal2380 · External reference
10.1016/j.cell.2007.02.005
10.1016/j.cell.2007.02.005 · External reference
Comparative DNA methylome analysis of endometrial carcinoma reveals complex and distinct deregulation of cancer promoters and enhancers
10.1186/1471-2164-15-868 · 2014 · External reference
Status and significance of CpG island methylator phenotype in endometrial cancer
10.1159/000324496 · 2011 · External reference
Assessing sirtuin expression in endometrial carcinoma and non-neoplastic endometrium
10.18632/oncotarget.6691 · 2016 · External reference
Direct monitoring of breast and endometrial cancer cell epigenetic response to DNA methyltransferase and histone deacetylase inhibitors
10.1016/j.bios.2019.111386 · 2019 · External reference
Enhancer of zeste homolog 2 is involved in the proliferation of endometrial carcinoma
10.3892/ol.2014.2437 · 2014 · External reference
10.18632/oncotarget.6350
10.18632/oncotarget.6350 · External reference
Overexpression of enhancer of zeste homolog 2 (EZH2) and focal adhesion kinase (FAK) in high grade endometrial carcinoma
2012 · External reference
Overexpression of enhancer of zeste homolog 2 (EZH2) and focal adhesion kinase (FAK) in high grade endometrial carcinoma
10.1016/j.ygyno.2012.07.128 · 2013 · External reference
10.1038/nature05915
10.1038/nature05915 · External reference
The chromatin accessibility landscape of primary human cancers
10.1126/science.aav1898 · 2018 · External reference
An integrative analysis of TFBS-clustered regions reveals new transcriptional regulation models on the accessible chromatin landscape
2015 · External reference
10.1093/bioinformatics/btx282
10.1093/bioinformatics/btx282 · External reference
Functional annotation of HOT regions in the human genome: implications for human disease and cancer
2015 · External reference
TRANSFAC: an integrated system for gene expression regulation
10.1093/nar/28.1.316 · 2000 · External reference
10.1093/nar/gkp950
10.1093/nar/gkp950 · External reference
10.1093/nar/gkq992
10.1093/nar/gkq992 · External reference
iFORM: Incorporating Find Occurrence of Regulatory Motifs
10.1371/journal.pone.0168607 · 2016 · External reference
10.1038/s41576-019-0114-6
10.1038/s41576-019-0114-6 · External reference
10.1016/j.cell.2017.09.042
10.1016/j.cell.2017.09.042 · External reference
10.1038/s41586-020-2214-z
10.1038/s41586-020-2214-z · External reference
10.1038/nature12113
10.1038/nature12113 · External reference
10.1038/s41586-020-2023-4
10.1038/s41586-020-2023-4 · External reference
10.1016/j.cell.2016.08.056
10.1016/j.cell.2016.08.056 · External reference
Immune Microenvironment in Microsatellite-Instable Endometrial Cancers: Hereditary or Sporadic Origin Matters
10.1158/1078-0432.ccr-16-2655 · 2017 · External reference
10.1038/s41586-021-03662-5
10.1038/s41586-021-03662-5 · External reference
10.1126/science.aar2555
10.1126/science.aar2555 · External reference
10.1016/j.cell.2018.06.006
10.1016/j.cell.2018.06.006 · External reference
Pervasive lesion segregation shapes cancer genome evolution
2019 · External reference
10.1038/s41586-019-1517-4
10.1038/s41586-019-1517-4 · External reference
10.1038/s41568-020-0290-x
10.1038/s41568-020-0290-x · External reference
10.1038/nature12634
10.1038/nature12634 · External reference
10.1126/science.1235122
10.1126/science.1235122 · External reference
10.1038/nature12912
10.1038/nature12912 · External reference
10.1093/bioinformatics/btu467
10.1093/bioinformatics/btu467 · External reference
10.1038/nm.4333
10.1038/nm.4333 · External reference
10.1038/s41568-018-0060-1
10.1038/s41568-018-0060-1 · External reference
DriverDBv3: a multi-omics database for cancer driver gene research
2020 · External reference
Upregulation of SCNN1A Promotes Cell Proliferation, Migration, and Predicts Poor Prognosis in Ovarian Cancer Through Regulating Epithelial-Mesenchymal Transformation
2019 · External reference
10.1038/s41388-018-0453-3
10.1038/s41388-018-0453-3 · External reference
MiR-29a-5p inhibits proliferation and invasion and induces apoptosis in endometrial carcinoma via targeting TPX2
10.1080/15384101.2018.1475829 · 2018 · External reference
10.1007/s00404-012-2706-7
10.1007/s00404-012-2706-7 · External reference
UBE2C Is Upregulated by Estrogen and Promotes Epithelial-Mesenchymal Transition via p53 in Endometrial Cancer
10.1158/1541-7786.mcr-19-0561 · 2020 · External reference
PRSS8 is Downregulated and Suppresses Tumour Growth and Metastases in Hepatocellular Carcinoma
10.1159/000453136 · 2016 · External reference
Decreased secretoglobin family 2A member 1expression is associated with poor outcomes in endometrial cancer
2020 · External reference
Mammaglobin B may be a prognostic biomarker of uterine corpus endometrial cancer
2020 · External reference
Expression of NRP-1 and NRP-2 in Endometrial Cancer
10.2174/1389201020666190219121602 · 2019 · External reference
ITE, an endogenous aryl hydrocarbon receptor ligand, suppresses endometrial cancer cell proliferation and migration
10.1016/j.tox.2019.03.017 · 2019 · External reference
Mutational Landscape and Antiproliferative Functions of ELF Transcription Factors in Human Cancer
10.1158/0008-5472.can-14-3816 · 2016 · External reference
10.1038/s41588-019-0494-8
10.1038/s41588-019-0494-8 · External reference
10.1093/nar/gky1025
10.1093/nar/gky1025 · External reference
